Publicacions (121) Publicacions de RAFAEL VÍCTOR ARROYO GONZÁLEZ

filter_list Allergy%2520and%2520Immunology

2017

  1. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis

    Multiple Sclerosis, Vol. 23, Núm. 10, pp. 1367-1376

  2. Conjoint analysis to understand preferences of patients with multiple sclerosis for disease-modifying therapy attributes in Spain: A cross-sectional observational study

    BMJ Open, Vol. 7, Núm. 3

  3. Fingolimod use for the treatment of multiple sclerosis in a clinical practice setting in Madrid

    Clinical Neuropharmacology, Vol. 40, Núm. 1, pp. 29-33

  4. Metabolomic signatures associated with disease severity in multiple sclerosis

    Neurology: Neuroimmunology and NeuroInflammation, Vol. 4, Núm. 2

  5. Multimarker risk stratification approach at multiple sclerosis onset

    Clinical Immunology, Vol. 181, pp. 43-50

  6. Revisión de las novedades del XXXII Congreso ECTRIMS 2016, presentadas en la IX Reunión Post-ECTRIMS (II)

    Revista de Neurologia, Vol. 65, Núm. 2, pp. 75-84

  7. Revisión de las novedades del XXXII congreso ectrims 2016, presentadas en la ix reunión post-ectrims (I)

    Revista de Neurologia, Vol. 65, Núm. 1, pp. 31-40

  8. Sodium intake and multiple sclerosis activity and progression in BENEFIT

    Annals of Neurology, Vol. 82, Núm. 1, pp. 20-29

  9. Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort

    European Journal of Clinical Investigation, Vol. 47, Núm. 2, pp. 158-166

2016

  1. A consensus initiative for the assessment of patients newly diagnosed with multiple sclerosis in Spain: the eXamina Project

    Neurodegenerative disease management, Vol. 6, Núm. 5, pp. 363-374

  2. Analysis of plasminogen genetic variants in multiple sclerosis patients

    G3: Genes, Genomes, Genetics, Vol. 6, Núm. 7, pp. 2073-2079

  3. Long-term adherence to IFN beta-1a treatment when using rebismart1device in patients with relapsing-remitting multiple sclerosis

    PLoS ONE, Vol. 11, Núm. 8

  4. Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients

    European Journal of Neurology, Vol. 23, Núm. 1, pp. 182-189

  5. Respuesta al tratamiento con interferón beta en pacientes con esclerosis múltiple. Validación del Rio Score

    Revista de Neurologia, Vol. 63, Núm. 4, pp. 145-150

  6. Revisión de las novedades del XXXI Congreso ECTRIMS 2015, presentadas en la VIII Reunión Post-ECTRIMS

    Revista de Neurologia, Vol. 62, Núm. 12, pp. 559-569

2015

  1. A functional variant that affects exon-skipping and protein expression of SP140 as genetic mechanism predisposing to multiple sclerosis

    Human Molecular Genetics, Vol. 24, Núm. 19, pp. 5619-5627

  2. A new risk variant for multiple sclerosis at the immunoglobulin heavy chain locus associates with intrathecal IgG, IgM index and oligoclonal bands

    Multiple Sclerosis, Vol. 21, Núm. 9, pp. 1104-1111

  3. Assessment of the reproducibility of oligoclonal IgM band detection for its application in daily clinical practice

    Clinica Chimica Acta, Vol. 438, pp. 67-69

  4. Consenso español actualizado sobre el uso del natalizumab (Tysabri®)-2013

    Neurologia, Vol. 30, Núm. 5, pp. 302-314

  5. Effects of diazoxide in multiple sclerosis: A randomized, double-blind phase 2 clinical trial

    Neurology: Neuroimmunology and NeuroInflammation, Vol. 2, Núm. 5, pp. e147